Neumología

Fibrosis Pulmonar Idiopática

Antifibrotic therapy (nintedanib, pirfenidone) and lung transplant evaluation.

Opciones de Tratamiento

Centros Recomendados

$2,500

Desde

7-21 días

Espera Típica

Planes de Tratamiento para Fibrosis Pulmonar Idiopática

Compare opciones basadas en evidencia en los principales hospitales chinos — precios transparentes, tiempos de espera y recuperación.

Plan Principal

Pirfenidone Antifibrotic Therapy (Annual)

Daily oral antifibrotic with quarterly LFT and PFT monitoring.

Tiempo de Espera

5-7 days

Estancia Hospitalaria

Annual maintenance

Recuperación

Outpatient

Precio Estimado

Approx. $3,500/year

Ver Introducción Detallada — Procedimiento, Comparación de Precios y Más

Comparación de Precios: China vs EE.UU.

🇨🇳 China

$2,500

🇺🇸 EE.UU.

$13,750+

Ahorre hasta $11,250 por tratamiento

Pasos del Procedimiento

Pre-treatment: HRCT chest + PFTs (FVC, DLCO) + 6MWT + ILD multidisciplinary review

Baseline LFTs + photosensitivity assessment

Pirfenidone titration: Week 1: 267mg TID, Week 2: 534mg TID, Week 3+: 801mg TID

Take with food to reduce GI side effects

Photosensitivity protection: strict sunscreen + sun avoidance

Monthly LFT monitoring for first 6 months

Every 3-6 months: FVC, DLCO, 6MWT

Continue indefinitely if tolerated and effective

What is Pirfenidone for IPF?

An oral antifibrotic drug that slows the progression of idiopathic pulmonary fibrosis by inhibiting multiple fibrotic pathways. Combined with comprehensive ILD care, it extends life expectancy and preserves lung function.

Why China?

Cost (annual): $2,500-$5,500 (domestic) vs. $95,000-$120,000 in the US
Domestic production: Chinese-made pirfenidone + nintedanib at fraction of Western prices
ILD expertise: China-Japan Friendship Hospital is Asia's leading ILD center
Comprehensive management: Integrated pulmonary rehab + O2 therapy + transplant evaluation

Who is a candidate?

Confirmed IPF (UIP pattern on HRCT or biopsy)
FVC 50-80% predicted (disease-modifying window)
ECOG 0-2
Unexplained progressive fibrosing ILD (now also indicated)

Outcomes

FVC decline reduction: ~50%. Disease progression slowing: significant. Median survival extension: 1-2 years vs untreated. Common adverse effects: GI upset (30%), photosensitivity (20%) — usually manageable.

Reservar Consulta Gratuita WhatsApp

Los precios son rangos indicativos en USD basados en tarifas publicadas. La cotización final depende de sus registros médicos y hospital seleccionado — solicite una estimación personalizada gratuita.